Aclaris Therapeutics financials
$5.28−2.76%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8M | $18.7M | $31.2M | $29.8M | $6.8M | $6.5M | $4.2M | $6.2M | $1.7M | $0.00 |
| Gross profit | $5.7M | $15.9M | $27.8M | $25.7M | $2.0M | $1.3M | $172.0K | $1.8M | $476.0K | $0.00 |
| Gross margin | 73.3% | 85.1% | 89.0% | 86.5% | 30.3% | 20.8% | 4.1% | 29.6% | 28.3% | — |
| Operating income | -$76.4M | -$141.9M | -$97.4M | -$89.9M | -$89.7M | -$50.9M | -$111.1M | -$84.8M | -$54.4M | -$48.6M |
| Net income | -$64.9M | -$132.1M | -$88.5M | -$86.9M | -$90.9M | -$51.0M | -$161.4M | -$132.7M | -$68.5M | -$48.1M |
| Net margin | −829.6% | −705.5% | −283.1% | −292.1% | −1344.0% | −787.0% | −3817.2% | −2158.0% | −4071.5% | — |
| Diluted EPS | $-0.53 | $-1.71 | $-1.27 | $-1.33 | $-1.60 | $-1.20 | $-3.90 | $-4.03 | $-2.44 | $-2.25 |
| EBITDA | -$73.6M | -$138.6M | -$123.4M | -$84.4M | -$64.5M | -$47.2M | -$85.4M | -$82.9M | -$54.0M | -$48.4M |
| Operating cash flow | -$47.1M | -$20.1M | -$78.3M | -$72.3M | -$76.5M | -$41.0M | -$97.2M | -$102.1M | -$54.7M | -$34.6M |
| Free cash flow | -$47.2M | -$20.2M | -$79.6M | -$72.9M | -$76.8M | -$41.5M | -$98.8M | -$103.4M | -$55.9M | -$34.8M |
| Diluted shares | 122.6M | 77.3M | 69.8M | 65.2M | 56.7M | 42.5M | 41.3M | 32.9M | 28.1M | 21.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $20.0M | $24.6M | $39.9M | $45.3M | $27.3M | $22.1M |
| Short-term investments | $70.8M | $89.0M | $79.2M | $172.3M | $164.1M | $32.1M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $10.7M |
| Total assets | $160.5M | $220.3M | $197.4M | $254.6M | $251.2M | $70.8M |
| Total liabilities | $57.4M | $64.8M | $40.2M | $57.0M | $53.9M | $33.1M |
| Shareholders' equity | $103.1M | $155.6M | $157.2M | $197.6M | $197.3M | $37.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology